openPR Logo
Press release

A New Antiviral Strategy Was Discovered For Treating COVID-19

A New Antiviral Strategy Was Discovered For Treating COVID-19

A research team led by Professor Hongzhe SUN, Norman & Cecilia Yip Professor in Bioinorganic Chemistry, Department of Chemistry, Faculty of Science, and Professor Kwok Yung YUEN, Henry Fok Professor in Infectious Diseases, Department of Microbiology, Li Ka Shing Faculty of Medicine of the University of Hong Kong (HKU), has discovered a novel antiviral strategy for treatment of COVID-19.

They discovered that a class of metallodrugs currently used in the treatment of other infectious diseases is showing efficacy to potently suppress SARS-CoV-2 replication and relieve viral-associated symptoms in an animal model. The findings provide a new and readily available therapeutic option with high clinical potential for infection with SARS-CoV-2.

SARS-CoV-2 is an emerging coronavirus that has caused over 30 million laboratory-confirmed cases and more than 1 million deaths globally of COVID-19 since December 2019.

As the process of developing an effective vaccine is still ongoing, another approach for prevention and treatment of the disease is to identify anti-COVID-19 agents from existing virus-specific antiviral drugs to repurpose their uses to target the new virus.

Clinical trials on a series of antiviral agents are still ongoing which have yet to demonstrate therapeutic efficacies. Therefore, greater efforts are needed to extend the evaluation to cover a wider spectrum of clinically approved drugs, which hopefully could open the way to alternative treatment strategies against the disease through some readily available channels.

Generally, metal compounds are used as anti-microbial agents; their antiviral activities have rarely been explored. After screening a series of metallodrugs and related compounds, the research team identified ranitidine bismuth citrate (RBC), a commonly used anti-ulcer drug which contains the metal Bismuth for treatment of Helicobacter pylori-associated infection, as a potent anti-SARS-CoV-2 agent, both in vitro and in vivo.

RBC targets the vital non-structural protein 13 (Nsp13), a viral helicase essential for SARS-CoV-2 to replicate, by displacing the crucial zinc(II) ions in the zinc-binding with Bismuth-ions, to potently suppress the activity of the helicase.

RBC has been demonstrated to greatly reduce viral loads by over 1,000-folds in SARS-CoV-2-infected cells. In particular, in a golden Syrian hamster model, RBC suppresses SARS-CoV-2 replications to reduce viral loads by ~100 folds in both the upper and lower respiratory tracts, and mitigates virus-associated pneumonia.

RBC remarkably diminishes the level of prognostic markers and other major pro-inflammatory cytokines and chemokines in severe COVID-19 cases of infected hamsters, compared to the Remdesivir-treated group and control group.

RBC exhibits a low cytotoxicity with a high selectivity index at 975 (the larger the number the safer the drug), as compared to Remdesivir which has a low selectivity index at 129. The finding indicates a wide window between the drug's cytotoxicity and antiviral activity, which allows a great flexibility in adjusting its dosages for treatment.

The team investigated the mechanisms of RBC on SARS-CoV-2 and revealed for the first time the vital Nsp13 helicase as a druggable target by RBC. It irreversibly kicks out the crucial zinc(II) ions in the zinc-binding domain to change it to bismuth-bound via a distinct metal displacement route.

The research findings highlight viral helicases as a druggable target, and the high clinical potential of bismuth(III) drugs and other metallodrugs for treatment of SARS-CoV-2 infections.

Huateng Pharma is a leading manufacturer of API's Intermediates, such as anti-viral intermediates. They are oseltamivir intermediates, remdesivir intermediates, favipiravir impurities and baloxavir marboxil intermediates, etc. We are able to provide the services of Anti-Viral intermediates' process development and scale-up production with capacities varying from gram to kilograms and multi tons.

Hunan Huateng Pharmaceutical Co. Ltd.
Lugu Business Plaza E1, Yuelu District, Changsha City, Hunan Province, P.R. China
zip code: 410205
Telephone: +86 731 89916275
Fax: +86 0731-82251112-818
Website: https://en.huatengsci.com
Email:sales@huatengusa.com

Human Huateng Pharmaceutical Co., Ltd. is a leading and professional manufacturer which can provide PEG derivatives, biochemical reagents, pharmaceutical intermediates, APIs, Vitamin D Derivatives and targeted anti-tumor drugs.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release A New Antiviral Strategy Was Discovered For Treating COVID-19 here

News-ID: 2170839 • Views: 559

More Releases from Hunan Huateng Pharmaceutical Co. Ltd.

Huateng Pharma Develops Systemic Antiparasitic Agent Fluralaner
Fluralaner is a systemic insecticide and acaricide that can be administered orally or topically. Bravecto is the trade name. The U.S. Food and Drug Administration (FDA) approved it for flea treatment in dogs under the trade name Bravecto in May 2014 and for topical treatment in cats in November 2019. Fluralaner is a novel isooxazoline broad-spectrum insecticide that acts on γ-aminobutyric acid (GABA) receptors and has good activity against ticks, fleas,
Huateng Pharma Develops Intermediates of Carfilzomib For Multiple Myeloma
Carfilzomib, a proteasome inhibitor, is indicated for the treatment of patients with multiple myeloma. Multiple myeloma (multiple myeloma, MM) is a malignant tumor originating from the B cell lineage, characterized by the clonal proliferation of malignant plasma cells in the bone marrow microenvironment, causing fractures and bone marrow failure, and is the second most common blood system disease in the world Tumors cannot be cured by traditional chemotherapy regimens. Bortezomib is the
Huateng Pharma Develops Intermediates of Semaglutide For TD2
According to the latest IDF Diabetes map, the global prevalence of diabetes reached 10.5% in 2021, with 537 million adults living with diabetes. China has become a disaster zone for diabetes, with the largest number of adults with diabetes in the world. In the past 10 years (2011-2021), the number of people with diabetes in China increased from 90 million to 140 million, an increase of 56%. The total number
The Future of Treatment For Type 2 Diabetes
Although the treatment of type 2 diabetes (T2DM) has made impressive progress in the past few decades, researchers are constantly searching for new treatments. How to better control blood glucose and reduce diabetes-related complications has become a hot topic in the field of T2DM research. Previously, The Lancet Diabetes Endocrinology published an in-depth review detailing novel therapeutic targets for T2DM, mechanisms of drug action, and corresponding hypoglycemic efficacy. It involves innovation

All 5 Releases


More Releases for RBC

RBC Wealth Management Market May See a Big Move | Emerging Players RBC, SYZ Grou …
A new research document is added in HTF MI database of 35 pages, titled as 'Competitor Profile: RBC Wealth Management' with detailed analysis, Competitive landscape, forecast and strategies. The study covers geographic analysis that includes regions like North America, Europe or Asia and important players/vendors such as RBC, RBC Wealth Management, BlueBay Asset Management, City National Bank, SMP Partners Group, SYZ Group, Envestnet, Artivest, Redtail, CircleBlack, Riskalyze, Vestmark, MoneyGuidePro.
Accelerate Alternative ETFs Now on the RBC Dominion Securities A+ Platform
Accelerate Financial Technologies Inc. (“Accelerate”) is pleased to announce that its suite of institutional-caliber alternative ETFs have been added to the RBC Dominion Securities A+ platform. The RBC Dominion Securities A+ platform includes carefully evaluated investment solutions from elite money managers worldwide. A+ replaces the emotions and guesswork of investing with a strictly rational and decisive approach to intelligent asset allocation. Accelerate’s alternative ETFs are designed to provide exposure to
RBC Wealth Management Market to Witness Huge Growth by 2025 | RBC, RBC Wealth Ma …
A new research document is added in HTF MI database of 35 pages, titled as 'Competitor Profile: RBC Wealth Management' with detailed analysis, Competitive landscape, forecast and strategies. The study covers geographic analysis that includes regions like Complete America, LATAM, Europe, Nordic regions, Oceania or Southeast Asia or Just Eastern Asia and important players/vendors such as RBC, RBC Wealth Management, BlueBay Asset Management, City National Bank, SMP Partners Group,
Hackerpost.co: FACEBOOK GRANTED SPOTIFY, NETFLIX, AND RBC ACCESS TO USERS’ FAC …
Hackerpost: The social networking site Facebook is in data-sharing partnership with Apple, Amazon, Microsoft, Spotify, Netflix, Royal Bank of Canada, Yahoo, and that’s just the beginning. Meetings with 50 former Facebook employees and corporate accomplices uncover that the Social-networking mammoth has conceded certain organizations with access to client information regardless of restrictions and protections. Facebook has clashed with the 2011 consent agreement with the Federal Trade Commission that has banished the
Pearson Medical Technologies and XchangeLabs to Exhibit at RBC Cardinal 2016
ALEXANDRIA, La., July 7, 2016 – Pearson Medical Technologies (Pearson), a leader in pharmacy automation solutions, will showcase at RBC Cardinal 2016 in Chicago, IL from July 20-23 with XchangeLabs. Pearson and XchangeLabs will be exhibiting in booth #2416, where retail and other pharmacies can learn more about the IP128APS Automated Multi-Dose Packaging System as well as XchangeLabs’ SiteMed® software, a new patient-centric medication adherence software solution compatible with the
Kimberley Neeson Nominated for RBC Canadian Woman Entrepreneur Award
Toronto, ON (Canada) – For the second consecutive year, Kimberley Neeson, President of Neeson & Associates Court Reporting and Captioning Inc., has been nominated to the prestigious RBC Canadian Woman Entrepreneur Awards in the category of The Bell Trailblazer Award. This year’s nomination is made even more special by the fact that Bell Canada itself asked Ms. Neeson if they could put her forward as a contender in this